English
Español
Log In
Email address
Password
Log in
Have you forgotten your password?
Communities & Collections
Research Outputs
Projects
Researchers
Statistics
Feedback
English
Español
Log In
Email address
Password
Log in
Have you forgotten your password?
Home
CRIS
Publications
Associations of Haemoglobin Values and Rate of Changes With MACE in the ASCEND-ND Randomised Clinical Trial
Export
Statistics
Options
Associations of Haemoglobin Values and Rate of Changes With MACE in the ASCEND-ND Randomised Clinical Trial
Journal
Nephrology Dialysis Transplantation
Date Issued
2022
Author(s)
Singh, Ajay K.
Macdougall, Iain C.
Johansen, Kirsten
Jha, Vivekanand
Correa-Rotter, Ricardo
Del Vecchio, Lucia
Cases Amenos, Aleix
Robertson, Michele
Mallett, Steve
Bailey, Christine K.
Cobitz, Alexander
Obrador, Gregorio
Facultad de Ciencias de la Salud - CampCM
Type
Resource Types::text::conference output::conference proceedings::conference paper
URL
https://scripta.up.edu.mx/handle/123456789/9758
Abstract
Background and aims: Rapid changes in haemoglobin (Hb) following treatment with erythropoiesis-stimulating agents (ESAs) in patients with anaemia of chronic kidney disease (CKD) have been suggested to be associated with adverse outcomes [1–3]. This exploratory post-hoc analysis was performed to investigate the association between absolute Hb values or Hb changes over a 4-week period and the occurrence of first adjudicated major adverse cardiovascular event (MACE) in CKD patients not on dialysis who were treated with either daprodustat or darbepoetin. Method: ASCEND-ND was an event driven, cardiovascular outcomes trial conducted in over 30 countries that randomized 3872 CKD patients not on dialysis with baseline Hb of 8–10 g/dL if not on a prior ESA, or 8–11 g/dL if receiving an ESA, to receive either oral, once-daily daprodustat (1937 patients) or subcutaneous darbepoetin (1935 patients). Available doses were daprodustat 1–24 mg once-daily and darbepoetin 20–400 µg total 4-weekly dose. The study was recently reported to have met the co-primary endpoints of non-inferiority for first occurrence of adjudicated MACE and mean Hb change from baseline to weeks 28 through 52 [4]. MACE was a composite of death from any cause, non-fatal myocardial infarction or non-fatal stroke, and events were adjudicated by an independent clinical events committee blinded to treatment assignment. In this exploratory post-hoc analysis, we examined the associations of post-randomization absolute Hb values and Hb changes categorized into quintiles (see Table 1) with first adjudicated MACE. Each patient's time in the study, prior to a first MACE or end of follow-up, was divided into distinct 4-week intervals, with each interval associated with a particular post-randomization Hb value and rate of change. Separately for each treatment group, these 4-week periods were grouped according to quintiles of Hb values, and MACE rates were calculated for each quintile. This analysis was repeated using quintiles derived from Hb rate of decrease and increase. MACEs that occurred prior to Week 4, the first scheduled post-randomization Hb collection, were not included in the analysis. Copyright © Oxford University Press
Views
9
Acquisition Date
Oct 4, 2024
View Details
Downloads
1
Acquisition Date
Oct 4, 2024
View Details
google-scholar
View Details